Herbert H. Loong

Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.

A. Shaw, E. Felip, F. D. De Braud, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

Y. Elamin, Herbert H. Loong, Koichi Goto, 2023, The New England journal of medicine.

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

S. Lim, Q. Ou, T. Reungwetwattana, 2023, Cancers.

NTRK gene fusion testing and management in lung cancer.

A. Drilon, D. Planchard, E. Rudzinski, 2024, Cancer treatment reviews.

Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.

G. Buchschacher, W. Bordogna, H. Zeuner, 2023, Lung cancer.